Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsy...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.781946/full |
| _version_ | 1798024675063758848 |
|---|---|
| author | Pavel Mohr Pavel Mohr Jirí Masopust Miloslav Kopeček Miloslav Kopeček |
| author_facet | Pavel Mohr Pavel Mohr Jirí Masopust Miloslav Kopeček Miloslav Kopeček |
| author_sort | Pavel Mohr |
| collection | DOAJ |
| description | Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsychotic efficacy of all three drugs was established in several placebo-controlled randomized trials (RCTs) in schizophrenia, both acute phase and relapse prevention. In addition, each of the DRPA agents has been tested in other psychiatric disorders, including bipolar disorder or major depression. However, a few studies have examined their comparative clinical efficacy. There are no head-to-head comparisons between aripiprazole, brexpiprazole, or cariprazine. In two acute schizophrenia RCTs of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. To assess potential differences in the efficacy of DRPAs, we reviewed data from controlled trials, systematic reviews, and meta-analyses. Our results showed that the acute antipsychotic effects of DRPAs, as measured by the number needed to treat, are comparable. The three agents were superior to placebo in acute treatment, and cariprazine was found to be effective in the reduction of primary negative symptoms of schizophrenia. In the therapy of bipolar disorder, aripiprazole and cariprazine showed antimanic efficacy, cariprazine was also effective in the management of bipolar depression, and aripiprazole was effective for relapse prevention. The addon administration of aripiprazole or brexpiprazole reduced symptoms of major depression. Aripiprazole can control acute agitation associated with psychosis or bipolar disorder; brexpiprazole showed the potential to manage agitation in dementia patients. Aripiprazole has also established evidence of efficacy in children and adolescents and other conditions: OCD, tic disorders, and autism spectrum disorder. Our review of published data suggests that in terms of clinical efficacy, DRPAs are a heterogeneous group, with each drug possessing its own therapeutic benefits. |
| first_indexed | 2024-04-11T18:06:29Z |
| format | Article |
| id | doaj.art-7aaa618d31094b61832604d277a5bf65 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-11T18:06:29Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-7aaa618d31094b61832604d277a5bf652022-12-22T04:10:19ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-01-011210.3389/fpsyt.2021.781946781946Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?Pavel Mohr0Pavel Mohr1Jirí Masopust2Miloslav Kopeček3Miloslav Kopeček4National Institute of Mental Health, Klecany, CzechiaFaculty of Medicine, Charles University, Prague, CzechiaPsychiatric Clinic of the University Hospital Hradec Kràlové, Charles University, Hradec Kràlové, CzechiaNational Institute of Mental Health, Klecany, CzechiaFaculty of Medicine, Charles University, Prague, CzechiaDopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsychotic efficacy of all three drugs was established in several placebo-controlled randomized trials (RCTs) in schizophrenia, both acute phase and relapse prevention. In addition, each of the DRPA agents has been tested in other psychiatric disorders, including bipolar disorder or major depression. However, a few studies have examined their comparative clinical efficacy. There are no head-to-head comparisons between aripiprazole, brexpiprazole, or cariprazine. In two acute schizophrenia RCTs of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. To assess potential differences in the efficacy of DRPAs, we reviewed data from controlled trials, systematic reviews, and meta-analyses. Our results showed that the acute antipsychotic effects of DRPAs, as measured by the number needed to treat, are comparable. The three agents were superior to placebo in acute treatment, and cariprazine was found to be effective in the reduction of primary negative symptoms of schizophrenia. In the therapy of bipolar disorder, aripiprazole and cariprazine showed antimanic efficacy, cariprazine was also effective in the management of bipolar depression, and aripiprazole was effective for relapse prevention. The addon administration of aripiprazole or brexpiprazole reduced symptoms of major depression. Aripiprazole can control acute agitation associated with psychosis or bipolar disorder; brexpiprazole showed the potential to manage agitation in dementia patients. Aripiprazole has also established evidence of efficacy in children and adolescents and other conditions: OCD, tic disorders, and autism spectrum disorder. Our review of published data suggests that in terms of clinical efficacy, DRPAs are a heterogeneous group, with each drug possessing its own therapeutic benefits.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.781946/fullantipsychoticsdopamine partial agonistsaripiprazolebrexpiprazolecariprazineclinical efficacy |
| spellingShingle | Pavel Mohr Pavel Mohr Jirí Masopust Miloslav Kopeček Miloslav Kopeček Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Frontiers in Psychiatry antipsychotics dopamine partial agonists aripiprazole brexpiprazole cariprazine clinical efficacy |
| title | Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? |
| title_full | Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? |
| title_fullStr | Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? |
| title_full_unstemmed | Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? |
| title_short | Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? |
| title_sort | dopamine receptor partial agonists do they differ in their clinical efficacy |
| topic | antipsychotics dopamine partial agonists aripiprazole brexpiprazole cariprazine clinical efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.781946/full |
| work_keys_str_mv | AT pavelmohr dopaminereceptorpartialagonistsdotheydifferintheirclinicalefficacy AT pavelmohr dopaminereceptorpartialagonistsdotheydifferintheirclinicalefficacy AT jirimasopust dopaminereceptorpartialagonistsdotheydifferintheirclinicalefficacy AT miloslavkopecek dopaminereceptorpartialagonistsdotheydifferintheirclinicalefficacy AT miloslavkopecek dopaminereceptorpartialagonistsdotheydifferintheirclinicalefficacy |